The 5-year DFS rates were 33.8% and 81.8% for patients with Her2+ and Her2− breast cancer, respectively (P < 0.0001, HR 12.27, 95% C.I.: 3.92–38.42), and the 5-year OAS rates were 41.7% and 83.2%, respectively (P = 0.001, HR 7.14, 95% C.I.: 2.21–23.06). This evidence concerns the gene ERBB2 and breast carcinoma.